English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Osteoporosis and fractures in liver disease: Relevance, pathogenesis and therapeutic implications

Nakchbandi, I. (2014). Osteoporosis and fractures in liver disease: Relevance, pathogenesis and therapeutic implications. WORLD JOURNAL OF GASTROENTEROLOGY, 20(28), 9427-9438. doi:10.3748/wjg.v20.i28.9427.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Nakchbandi, Inaam1, Author              
Affiliations:
1Nakchbandi, Inaam / Translational Medicine, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565162              

Content

show
hide
Free keywords: PRIMARY BILIARY-CIRRHOSIS; BONE-MINERAL DENSITY; CHRONIC HEPATITIS-C; VITAMIN-D-RECEPTOR; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-I; HORMONE REPLACEMENT THERAPY; OSTEOBLAST FUNCTION; CIRCULATING LEVELS; PRIMARY HYPERPARATHYROIDISMOsteoporosis; Liver disease; Fracture; Prevalence; Pathogenesis; Fibronectin; Insulin like growth factor-I; Therapy; Vitamin D; Calcium;
 Abstract: It is being increasingly recognized that patients with liver disease develop bone loss that can be severe enough to lead to atraumatic fractures and thus markedly diminish life quality and expectancy. The estimated prevalence for liver-related osteoporosis is between 20-420/100000 of the general population, and fractures between 60-880/100000. It should be kept in mind that up to 40% of patients with chronic liver disease may experience a fracture. The pathogenic mediators include fibronectin, insulin like growth factor-I, and various cytokines, but decreased vitamin D and/or treatment with corticosteroids contribute to worsening bone health. Despite the advances in bone biology that have shed some light on the pathogenesis of this bone loss, treatment options remain nonspecific and tightly linked to treatments of other forms of osteoporosis. Thus, treatment should include calcium and vitamin D supplementation in all patients with chronic liver disease. Therapy with bisphosphonates should be considered, especially in patients receiving corticosteroids. This review focuses on the prevalence of this entity as well as the evidence available with regard to the pathogenesis of bone loss in liver disease, the diagnostic steps required in all patients, and the therapeutic options available. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

Details

show
hide
Language(s): eng - English
 Dates: 2014
 Publication Status: Published in print
 Pages: 12
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: ISI: 000339389800024
DOI: 10.3748/wjg.v20.i28.9427
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: WORLD JOURNAL OF GASTROENTEROLOGY
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: 8226 REGENCY DR, PLEASANTON, CA 94588 USA : BAISHIDENG PUBLISHING GROUP INC
Pages: - Volume / Issue: 20 (28) Sequence Number: - Start / End Page: 9427 - 9438 Identifier: ISSN: 1007-9327